KENya Single-dose HPV-vaccine Efficacy – The KEN-SHE Study
The KEN-SHE Study will compare immediate, single-dose HPV 16/18 and HPV 16/18/31/33/45/52/58/6/11 vaccination (and delayed meningococcal immunization) with delayed HPV vaccination (and immediate meningococcal immunization) among young women age 15-20 years. For more information, see www.kenshestudy.org.
Countries
Active Dates
07/01/2018 to 04/30/2023
Faculty Involved
Health Topics